生成一代蛋白酶体抑制剂：从微生物发酵到萨利司莫司 A（美罗华）和其他萨利司莫司的全合成。
Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides.
机构信息
Nereus Pharmaceuticals, Inc., 10480 Wateridge Circle, San Diego, CA 92121, USA.
出版信息
Mar Drugs. 2010 Mar 25;8(4):835-80. doi: 10.3390/md8040835.
Abstract
The salinosporamides are potent proteasome inhibitors among which the parent marine-derived natural product salinosporamide A (marizomib; NPI-0052; 1) is currently in clinical trials for the treatment of various cancers. Methods to generate this class of compounds include fermentation and natural products chemistry, precursor-directed biosynthesis, mutasynthesis, semi-synthesis, and total synthesis. The end products range from biochemical tools for probing mechanism of action to clinical trials materials; in turn, the considerable efforts to produce the target molecules have expanded the technologies used to generate them. Here, the full complement of methods is reviewed, reflecting remarkable contributions from scientists of various disciplines over a period of 7 years since the first publication of the structure of 1.
摘要
沙利度胺类似物是强效的蛋白酶体抑制剂，其中母体海洋来源天然产物沙利度胺 A（NPI-0052；1）目前正处于临床试验阶段，用于治疗各种癌症。这类化合物的生成方法包括发酵和天然产物化学、前体定向生物合成、突变合成、半合成和全合成。最终产物从作用机制研究的生化工具到临床试验材料不等；反过来，为生产目标分子所做的大量努力也扩展了生成它们所使用的技术。在此，综述了所有方法，反映了自 1 的结构首次发表以来的 7 年中，来自不同学科的科学家的显著贡献。
相似文献
1
Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides.
Mar Drugs. 2010 Mar 25;8(4):835-80. doi: 10.3390/md8040835.
2
Marizomib, a potent second generation proteasome inhibitor from natural origin.
Anticancer Agents Med Chem. 2015;15(3):298-306. doi: 10.2174/1871520614666141114202606.
3
Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
Mol Pharmacol. 2014 Jul;86(1):12-9. doi: 10.1124/mol.114.092114. Epub 2014 Apr 15.
4
Salinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics.
Angew Chem Int Ed Engl. 2010 Dec 3;49(49):9346-67. doi: 10.1002/anie.201000728.
5
Salinosporamides D-J from the marine actinomycete Salinispora tropica, bromosalinosporamide, and thioester derivatives are potent inhibitors of the 20S proteasome.
J Nat Prod. 2007 Feb;70(2):269-76. doi: 10.1021/np0603471. Epub 2007 Jan 23.
6
Bacterial self-resistance to the natural proteasome inhibitor salinosporamide A.
ACS Chem Biol. 2011 Nov 18;6(11):1257-64. doi: 10.1021/cb2002544. Epub 2011 Sep 26.
7
Synthesis of salinosporamide A and its analogs as 20S proteasome inhibitors and SAR summarization.
Curr Top Med Chem. 2011 Dec;11(23):2906-22. doi: 10.2174/156802611798281302.
8
Marizomib (Salinosporamide A) Promotes Apoptosis in A375 and G361 Melanoma Cancer Cells.
Mar Drugs. 2024 Jul 15;22(7):315. doi: 10.3390/md22070315.
9
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Curr Cancer Drug Targets. 2011 Mar;11(3):254-84. doi: 10.2174/156800911794519716.
10
Enzymatic assembly of the salinosporamide γ-lactam-β-lactone anticancer warhead.
Nat Chem Biol. 2022 May;18(5):538-546. doi: 10.1038/s41589-022-00993-w. Epub 2022 Mar 21.
引用本文的文献
1
Marizomib in the therapy of brain tumors-how far did we go and where do we stand?
Pharmacol Rep. 2025 May 29. doi: 10.1007/s43440-025-00739-0.
2
Enantioselective total synthesis of (+)-cylindricine B.
Chem Sci. 2024 Sep 13;15(40):16554-8. doi: 10.1039/d4sc04910a.
3
Natural Compounds as Protease Inhibitors in Therapeutic Focus on Cancer Therapy.
Anticancer Agents Med Chem. 2024;24(16):1167-1181. doi: 10.2174/0118715206303964240708095110.
4
Evolution of Natural Product Scaffolds as Potential Proteasome Inhibitors in Developing Cancer Therapeutics.
Metabolites. 2023 Mar 31;13(4):509. doi: 10.3390/metabo13040509.
5
The oxazolomycin family: a review of current knowledge.
RSC Adv. 2020 Nov 9;10(67):40745-40794. doi: 10.1039/d0ra08396h.
6
Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes.
Mar Drugs. 2020 Dec 4;18(12):619. doi: 10.3390/md18120619.
7
Targeting eukaryotic proteases for natural products-based drug development.
Nat Prod Rep. 2020 Jun 24;37(6):827-860. doi: 10.1039/c9np00060g.
8
Highlights of marine natural products having parallel scaffolds found from marine-derived bacteria, sponges, and tunicates.
J Antibiot (Tokyo). 2020 Aug;73(8):504-525. doi: 10.1038/s41429-020-0330-5. Epub 2020 Jun 8.
9
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.
Pharmacol Ther. 2020 Sep;213:107579. doi: 10.1016/j.pharmthera.2020.107579. Epub 2020 May 19.
10
From Seabed to Bedside: A Review on Promising Marine Anticancer Compounds.
Biomolecules. 2020 Feb 6;10(2):248. doi: 10.3390/biom10020248.
本文引用的文献
1
Formal synthesis of salinosporamide A via NHC-catalyzed intramolecular lactonization.
Tetrahedron. 2009 Jun 27;65(26):4957-4967. doi: 10.1016/j.tet.2009.03.103.
2
Engineering fluorometabolite production: fluorinase expression in Salinispora tropica Yields Fluorosalinosporamide.
J Nat Prod. 2010 Mar 26;73(3):378-82. doi: 10.1021/np900719u.
3
Function-oriented biosynthesis of beta-lactone proteasome inhibitors in Salinispora tropica.
J Med Chem. 2009 Oct 8;52(19):6163-7. doi: 10.1021/jm901098m.
4
Snapshots of the fluorosalinosporamide/20S complex offer mechanistic insights for fine tuning proteasome inhibition.
J Med Chem. 2009 Sep 10;52(17):5420-8. doi: 10.1021/jm900559x.
5
In vitro mutasynthesis of lantibiotic analogues containing nonproteinogenic amino acids.
J Am Chem Soc. 2009 Sep 2;131(34):12024-5. doi: 10.1021/ja903239s.
6
New, highly active nonbenzoquinone geldanamycin derivatives by using mutasynthesis.
Chembiochem. 2009 Jul 20;10(11):1801-5. doi: 10.1002/cbic.200900246.
7
The role of ubiquitin in NF-kappaB regulatory pathways.
Annu Rev Biochem. 2009;78:769-96. doi: 10.1146/annurev.biochem.78.070907.102750.
8
Genetic engineering of antibiotic biosynthesis for the generation of new aminocoumarins.
Biotechnol Adv. 2009 Nov-Dec;27(6):1006-1014. doi: 10.1016/j.biotechadv.2009.05.017. Epub 2009 May 20.
9
Targeted therapy in acute myeloid leukaemia: current status and future directions.
Expert Opin Investig Drugs. 2009 Apr;18(4):433-55. doi: 10.1517/14728220902787628.
10
Effect of cobalt and vitamin B12 on the production of salinosporamides by Salinispora tropica.
J Antibiot (Tokyo). 2009 Apr;62(4):213-6. doi: 10.1038/ja.2009.7. Epub 2009 Feb 6.
Zotero 插件